Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jeff Jones maintains an Outperform rating on Corbus Pharmaceuticals (NASDAQ:CRBP) and raises the price target from $60 to $80.
June 03, 2024 | 12:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Jeff Jones maintains an Outperform rating on Corbus Pharmaceuticals and raises the price target from $60 to $80.
The raised price target from $60 to $80 and the maintained Outperform rating by a reputable analyst at Oppenheimer is likely to positively impact investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100